Related Experiment Videos
Complementary memory storage sites in mice: their development as affected by the competitive NMDA receptor
A C Church1, J B Flexner, L B Flexner
1Advanced Systems Unit, Interpol, Washington, DC 20530, USA.
Pharmacology, Biochemistry, and Behavior
|September 1, 1995
Summary
Puromycin injections cause amnesia in mice, but lose effectiveness after 6 days. NMDA receptor antagonist CPP blocks complementary memory site development, suggesting NMDA receptor-dependent calcium is crucial for memory consolidation.
Area of Science:
- Neuroscience
- Memory Consolidation
- Molecular Biology
Background:
- Puromycin induces amnesia in mice for aversive maze learning within 3 days of training.
- Amnestic effectiveness of puromycin diminishes if injections are delayed beyond 6 days post-training.
- Central adrenergic and cholinergic systems are implicated in memory consolidation processes.
Purpose of the Study:
- To investigate the role of NMDA receptors in the development of complementary memory storage sites.
- To determine if NMDA receptor antagonism affects the time-dependent development of memory consolidation.
- To explore the involvement of NMDA receptor-dependent calcium in memory storage site formation.
Main Methods:
- Bitemporal puromycin injections in mice at varying intervals post-aversive maze training.
- Administration of the NMDA receptor antagonist CPP.
- Observation of amnestic effects and memory retention.
Main Results:
- Puromycin injections were effective in inducing amnesia within 3 days but not after 6 days.
- Administration of CPP blocked the development of complementary memory storage sites.
- Evidence suggests NMDA receptor-dependent postsynaptic calcium is essential for memory storage site development.
Conclusions:
- Complementary memory storage sites develop within 6 days post-training.
- NMDA receptor activity is critical for the formation of these complementary memory sites.
- NMDA receptor-dependent calcium influx is essential for triggering the development of memory storage sites.